Clinical Trial Update: Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating surufatinib alone or with anti-PD-1 monoclonal antibody for advanced hepatocellular carcinoma; status not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Anti-PD-1 Monoclonal Antibody
• Surufatinib (Surufatinib)

Snippet

Sponsor: Zhongnan Hospital | Conditions: Hepatocellular Carcinoma; Targeted Therapy; Progression-free Survival | Phase 2 | Status: UNKNOWN